Research Progress of Correlation and Underlying Mechanisms between Metabolic Syndrome and Alzheimer's Disease

doi:10.12114/j.issn.1007-9572.2023.0393

Abstract

Abstract:

Recent studies have identified a trend toward cognitive decline and even progression to dementia in patients with metabolic syndrome (MetS), and Alzheimer's disease (AD) is the most important subtype of dementia. In reviewing the correlation between cognitive impairment due to MetS and development of AD in previous studies, this paper highlights the growing body of data that supports MetS as a whole as well as its components of hypertension and hyperglycemia as risk factors for AD, whereas insulin resistance, neurologic chronic inflammation, and adipokine disorders play important roles in the pathogenesis. Since there are now no viable treatment alternatives available to stop or reverse the degenerative progression of AD, it is expected to provide scientific evidence for a comprehensive strategy for early prevention and treatment of AD by targeting relatively curable MetS for intervention.

Key words: Metabolic syndrome, Alzheimer disease, Hyperglycemia, Cognitive dysfunction, Insulin resistance, Hypertension, Obesity, abdominal, Dyslipidemias

摘要：

近期研究发现代谢综合征（MetS）患者有认知功能下降甚至向痴呆进展的趋势，而阿尔茨海默病（AD）是痴呆最重要的分型。本文回顾总结既往研究中MetS导致的认知功能障碍与AD发病的相关性，指出有较多证据支持MetS作为整体及其组分中的高血压、高血糖是AD的危险因素，而胰岛素抵抗、神经慢性炎症、脂肪因子紊乱等在发病过程中起到重要作用，因尚缺乏可有效延缓或逆转AD病理进展的治疗方案，期待以相对可治MetS为干预靶标，为早期防治AD综合策略的制订提供科学证据。

关键词: 代谢综合征, 阿尔茨海默病, 高血糖症, 认知功能障碍, 胰岛素抵抗, 高血压, 肥胖，腹部, 血脂异常

LI Yaping,LI Xia. Research Progress of Correlation and Underlying Mechanisms between Metabolic Syndrome and Alzheimer's Disease[J]. Chinese General Practice, 2024, 27(03): 268-272. DOI: 10.12114/j.issn.1007-9572.2023.0393.
李雅萍,李霞. 代谢综合征与阿尔茨海默病的相关性及机制研究进展[J]. 中国全科医学, 2024, 27(03): 268-272. DOI: 10.12114/j.issn.1007-9572.2023.0393.

References 40

[1]	任汝静，殷鹏，王志会，等. 中国阿尔茨海默病报告2021[J].诊断学理论与实践，2021，20（4）：317-337. DOI：10.16150/j.1671-2870.2021.04.001.
[2]	2022 Alzheimer's disease facts and figures[J]. Alzheimers Dement，2022，18（4）：700-789. DOI：10.1002/alz.12638.
[3]	ZUIN M，RONCON L，PASSARO A，et al. Metabolic syndrome and the risk of late onset Alzheimer's disease：an updated review and meta-analysis[J]. Nutr Metab Cardiovasc Dis，2021，31（8）：2244-2252. DOI：10.1016/j.numecd.2021.03.020.
[4]	LEE J E，SHIN D W，HAN K，et al. Changes in metabolic syndrome status and risk of dementia[J]. J Clin Med，2020，9（1）：122. DOI：10.3390/jcm9010122.
[5]	CHO Y，HAN K，KIM D H，et al. Cumulative exposure to metabolic syndrome components and the risk of dementia：a nationwide population-based study[J]. Endocrinol Metab，2021，36（2）：424-435. DOI：10.3803/EnM.2020.935.
[6]	AKBARALY T N，KIVIMAKI M，SHIPLEY M J，et al. Metabolic syndrome over 10 years and cognitive functioning in late midlife：the WhitehallⅡstudy[J]. Diabetes Care，2010，33（1）：84-89. DOI：10.2337/dc09-1218.
[7]	PAL K，MUKADAM N，PETERSEN I，et al. Mild cognitive impairment and progression to dementia in people with diabetes，prediabetes and metabolic syndrome：a systematic review and meta-analysis[J]. Soc Psychiatry Psychiatr Epidemiol，2018，53（11）：1149-1160. DOI：10.1007/s00127-018-1581-3.
[8]	CUMMINGS J，ORTIZ A，CASTELLINO J，et al. Diabetes：risk factor and translational therapeutic implications for Alzheimer's disease[J]. Eur J Neurosci，2022，56（9）：5727-5757. DOI：10.1111/ejn.15619.
[9]	SÁIZ-VAZQUEZ O，PUENTE-MARTÍNEZ A，PACHECO-BONROSTRO J，et al. Blood pressure and Alzheimer's disease：a review of meta-analysis[J]. Front Neurol，2023，13：1065335. DOI：10.3389/fneur.2022.1065335.
[10]	LENNON M J，MAKKAR S R，CRAWFORD J D，et al. Midlife hypertension and Alzheimer's disease：a systematic review and meta-analysis[J]. J Alzheimers Dis，2019，71（1）：307-316. DOI：10.3233/JAD-190474.
[11]	LENNON M J，KONCZ R，SACHDEV P S. Hypertension and Alzheimer's disease：is the picture any clearer?[J]. Curr Opin Psychiatry，2021，34（2）：142-148. DOI：10.1097/YCO.0000000000000684.
[12]	KUEHN B M. In Alzheimer research，glucose metabolism moves to center stage[J]. JAMA，2020，323（4）：297-299. DOI：10.1001/jama.2019.20939.
[13]	RAMIREZ A，WOLFSGRUBER S，LANGE C，et al. Elevated HbA_1c is associated with increased risk of incident dementia in primary care patients[J]. J Alzheimers Dis，2015，44（4）：1203-1212. DOI：10.3233/JAD-141521.
[14]	LI T C，YANG C P，TSENG S T，et al. Visit-to-visit variations in fasting plasma glucose and HbA_1c associated with an increased risk of alzheimer disease：diabetes study[J]. Diabetes Care，2017，40（9）：1210-1217. DOI：10.2337/dc16-2238.
[15]	DYE L，BOYLE N B，CHAMP C，et al. The relationship between obesity and cognitive health and decline[J]. Proc Nutr Soc，2017，76（4）：443-454. DOI：10.1017/S0029665117002014.
[16]	GANGULI M，BEER J C，ZMUDA J M，et al. Aging，diabetes，obesity，and cognitive decline：a population-based study[J]. J Am Geriatr Soc，2020，68（5）：991-998. DOI：10.1111/jgs.16321.
[17]	ALFORD S，PATEL D，PERAKAKIS N，et al. Obesity as a risk factor for Alzheimer's disease：weighing the evidence[J]. Obes Rev，2018，19（2）：269-280. DOI：10.1111/obr.12629.
[18]	QIZILBASH N，GREGSON J，JOHNSON M E，et al. BMI and risk of dementia in two million people over two decades：a retrospective cohort study[J]. Lancet Diabetes Endocrinol，2015，3（6）：431-436. DOI：10.1016/S2213-8587(15)00033-9.
[19]	GUO J，WANG J，DOVE A，et al. Body mass index trajectories preceding incident mild cognitive impairment and dementia[J]. JAMA Psychiatry，2022，79（12）：1180-1187. DOI：10.1001/jamapsychiatry.2022.3446.
[20]	NORTON S，MATTHEWS F E，BARNES D E，et al. Potential for primary prevention of Alzheimer's disease：an analysis of population-based data[J]. Lancet Neurol，2014，13（8）：788-794. DOI：10.1016/S1474-4422(14)70136-X.
[21]	PARDO-MORENO T，MOHAMED-MOHAMED H，RIVAS-DOMINGUEZ A，et al. Poor cognitive agility conservation in obese aging people[J]. Biomedicines，2023，11（1）：138. DOI：10.3390/biomedicines11010138.
[22]	TANG X Y，ZHAO W，LU M，et al. Relationship between central obesity and the incidence of cognitive impairment and dementia from cohort studies involving 5，060，687 participants[J]. Neurosci Biobehav Rev，2021，130：301-313. DOI：10.1016/j.neubiorev.2021.08.028.
[23]	HOU Q T，GUAN Y，YU W H，et al. Associations between obesity and cognitive impairment in the Chinese elderly：an observational study[J]. Clin Interv Aging，2019，14：367-373. DOI：10.2147/CIA.S192050.
[24]	LUCHSINGER J A，CHENG D，TANG M X，et al. Central obesity in the elderly is related to late-onset Alzheimer disease[J]. Alzheimer Dis Assoc Disord，2012，26（2）：101-105. DOI：10.1097/WAD.0b013e318222f0d4.
[25]	DIMACHE A M，ȘALARU D L，SASCĂU R，et al. The role of high triglycerides level in predicting cognitive impairment：a review of current evidence[J]. Nutrients，2021，13（6）：2118. DOI：10.3390/nu13062118.
[26]	BERNATH M M，BHATTACHARYYA S，NHO K，et al. Serum triglycerides in alzheimer disease：relation to neuroimaging and CSF biomarkers[J]. Neurology，2020，94（20）：e2088-2098. DOI：10.1212/WNL.0000000000009436.
[27]	CHEW H，SOLOMON V A，FONTEH A N. Involvement of lipids in Alzheimer's disease pathology and potential therapies[J]. Front Physiol，2020，11：598. DOI：10.3389/fphys.2020.00598.
[28]	ZHU Y，LIU X，ZHU R X，et al. Lipid levels and the risk of dementia：a dose-response meta-analysis of prospective cohort studies[J]. Ann Clin Transl Neurol，2022，9（3）：296-311. DOI：10.1002/acn3.51516.
[29]	AGARWAL M，KHAN S. Plasma lipids as biomarkers for Alzheimer's disease：a systematic review[J]. Cureus，2020，12（12）：e12008. DOI：10.7759/cureus.12008.
[30]	IQBAL G，BRAIDY N，AHMED T. Blood-based biomarkers for predictive diagnosis of cognitive impairment in a Pakistani population[J]. Front Aging Neurosci，2020，12：223. DOI：10.3389/fnagi.2020.00223.
[31]	WALKER J M，HARRISON F E. Shared neuropathological characteristics of obesity，type 2 diabetes and Alzheimer's disease：impacts on cognitive decline[J]. Nutrients，2015，7（9）：7332-7357. DOI：10.3390/nu7095341.
[32]	AN Y，VARMA V R，VARMA S，et al. Evidence for brain glucose dysregulation in Alzheimer's disease[J]. Alzheimers Dement，2018，14（3）：318-329. DOI：10.1016/j.jalz.2017.09.011.
[33]	ROJAS M，CHÁVEZ-CASTILLO M，PIRELA D，et al. Metabolic syndrome：is it time to add the central nervous system?[J]. Nutrients，2021，13（7）：2254. DOI：10.3390/nu13072254.
[34]	MICHAILIDIS M，MORAITOU D，TATA D A，et al. Alzheimer's disease as type 3 diabetes：common pathophysiological mechanisms between Alzheimer's disease and type 2 diabetes[J]. Int J Mol Sci，2022，23（5）：2687. DOI：10.3390/ijms23052687.
[35]	SÁNCHEZ-SARASÚA S，FERNÁNDEZ-PÉREZ I，ESPINOSA-FERNÁNDEZ V，et al. Can we treat neuroinflammation in Alzheimer's disease?[J]. Int J Mol Sci，2020，21（22）：8751. DOI：10.3390/ijms21228751.
[36]	ROJAS-GUTIERREZ E，MUÑOZ-ARENAS G，TREVIÑO S，et al. Alzheimer's disease and metabolic syndrome：a link from oxidative stress and inflammation to neurodegeneration[J]. Synapse，2017，71（10）：e21990. DOI：10.1002/syn.21990.
[37]	FORNY-GERMANO L，DE FELICE F G，VIEIRA M N D N. The role of leptin and adiponectin in obesity-associated cognitive decline and Alzheimer's disease[J]. Front Neurosci，2019，12：1027. DOI：10.3389/fnins.2018.01027.
[38]	PÉREZ-GONZÁLEZ R，ALVIRA-BOTERO M X，ROBAYO O，et al. Leptin gene therapy attenuates neuronal damages evoked by amyloid-β and rescues memory deficits in APP/PS1 mice[J]. Gene Ther，2014，21（3）：298-308. DOI：10.1038/gt.2013.85.
[39]	MOOLDIJK S S，IKRAM M K，IKRAM M A. Adiponectin，leptin，and resistin and the risk of dementia[J]. J Gerontol Ser A Biol Sci Med Sci，2022，77（6）：1245-1249. DOI：10.1093/gerona/glab267.
[40]	NG R C L，CHAN K H. Potential neuroprotective effects of adiponectin in Alzheimer's disease[J]. Int J Mol Sci，2017，18（3）：592. DOI：10.3390/ijms18030592.